Ergomed Share Discussion Threads

[bermudashorts] 28/6/2018 09:17

Yes, think disastrous RNS is probably a bit OTT - very disappointing more like it, especially given the Company's previous bullish statements.

[tsmith2] 28/6/2018 09:12

what current market cap? Seems toppy..

[sicilian_kan] 28/6/2018 09:02

Mirabeau this isn't really a pharma stock. It is a CRO with a pharmacovigilance arm that it is expanding.

[mirabeau] 28/6/2018 08:46

What a mess. I only set up the thread and never held a position but how many pharma stocks in recent weeks have released seriously disastrous RNSs...too numerous to mention

[sicilian_kan] 28/6/2018 08:44

Seems completely overdone to me.

- 5% reduction in revenue compared to market consensus, yet a 33% reduction in share price.


- 2018 EBITDA still going to be ahead of 2017's £2.8m

- Backlog of contracts still strong and increase on last years

- The Company's cash position remains strong with positive cash flows in the period.

I have only a small amount here. Invested 18 months ago on a 5 year basis. See no reason to bail out. Strategy and management still seem strong and am excited by the pharmacovigilance opportunities.

[sicilian_kan] 25/5/2018 16:44

Agreed and a nice rise too. I think we should be looking at testing 300p at some point in the coming weeks / months.

[bermudashorts] 25/5/2018 07:45

Decent RNS this morning, Dr. Michael Forstner, ex Roche and Boehringer-Ingelheim appears to be a good appointment.

[18bt] 25/5/2018 07:38

SP rise seems to confirm breakout above 212p area

[mfhmfh] 24/5/2018 17:16

BlackRock, Inc. at 5%

[mfhmfh] 24/5/2018 14:19

positive write up in Shares magazine today.

[jamtomorrow2] 19/5/2018 14:20

Not the best analogy. Rome burned down!

[sicilian_kan] 19/5/2018 11:12

Rome wasn't built in a day. But it was built.

[ih_433513] 18/5/2018 16:56

Presumably the co-partnership costs will continue at least in part for another year or so. And they’ve got to pay more for Haemostatix as well as any future acquisitions, which they certainly intend to make, so I’m not so convinced that profitability will be at the levels that you are predicting. I am also concerned about their accounting prowess bearing in mind the last minute profit warning when late adjustments of £900,000 were announced out of the blue.

[sicilian_kan] 18/5/2018 15:56

Strip out the R&D costs of the old co-partnering strategy (£2.7m) and the costs of acquisitions and they would have made a net profit. The core fundamentals of the business going forwards are very strong and the growth prospects are already proven to be very high.

[sicilian_kan] 18/5/2018 10:07

This is the link:



jamtomorrow, change in business strategy. Much higher growth in other less risky areas will be focused on - I see this as the prime driver behind the recent growth in sp:

· Net service revenue growth of 36% driving total revenue growth of 21%
· Within services, Drug Safety & Medical Information (pharmacovigilance) revenue grew 67%

PrimeVigilance's strategy of investing in people and technology is designed to drive further growth with the aim of becoming the global leader in pharmacovigilance by 2020. The global pharmacovigilance market is forecast to grow to more than $8 billion by 2024 from around $3 billion in 2015, with contract outsourcing forecast to expand from around 30% of the market in 2015 to approximately 50% in 2024. [see results rns]

"Net service revenue from the DS&MI segment, increased 68% to £22.3 million in 2017 from £13.3 million in 2016. Excluding the PharmInvent acquisition (completed in November 2016), organic growth of the DS&MI segment was 35%."

[jamtomorrow2] 17/5/2018 12:08

They are now going to partner out the Phase 3 Haemostatix trial. I thought that was a rather odd decision. A CRO like Ergo could carry out the trial on the cheap but they elect to partner it out and presumably reduce their potential take by at least 50%. Anyway it’s taking a while to find a partner isn’t it? Also Ferrer seems to be struggling to find a partner to progress its insomnia drug. And finally I see that Cel-Sci is expecting the results from the Multikine Phase 3 shortly. That would be a nice surprise if the results were positive, which not many people are expecting.

[mfhmfh] 17/5/2018 09:29

'fair value of 266-292p. The Development and Haemostatix businesses add a further 120p to that range'

Latest equity development report from 15th May:

hxxps://www.equitydevelopment.co.uk/company/?company=Ergomed+PLC&c=2QTO

[bermudashorts] 17/5/2018 08:22

Thanks SK - will check it out.

[sicilian_kan] 17/5/2018 08:02

There is a good video interview from the time of the last announcement setting things out.

[bermudashorts] 17/5/2018 07:36

Have to admit that I've taken my eye off the ball here - need to read up again on state of play with co-development partnerships and timescales of any possible news.